

Form 605Corporations Act 2001
Section 671B**Notice of ceasing to be a substantial holder**To Company Name/Scheme **CYCLOPHARM LIMITED**ACN/ARSN **116 931 250****1. Details of substantial holder (1)**Name **LLOYDS & CASANOVE INVESTMENT PARTNERS LIMITED**ACN/ARSN (if applicable) **N/A**The holder ceased to be a substantial holder on **30/12/2016**The previous notice was given to the company on **03/05/2013**The previous notice was dated **02/05/2013****2. Changes in relevant interests**

Particulars of each change in, or change in the nature of, a relevant interest (2) of the substantial holder or an associate (3) in voting securities of the company or scheme, since the substantial holder was last required to give a substantial holding notice to the company or scheme are as follows:

Date of change	Person whose relevant interest changed	Nature of change (4)	Consideration given in relation to change (5)	Class (6) and number of securities affected	Person's votes affected
		REFER TO ANNEXURE A			

3. Changes in association

The persons who have become associates (3) of, ceased to be associates of, or have changed the nature of their association (7) with, the substantial holder in relation to voting interests in the company or scheme are as follows:

Name and ACN/ARSN (if applicable)	Nature of association
Not applicable	

4. Addresses

The addresses of persons named in this form are as follows:

Name	Address
LLOYDS & CASANOVE INVESTMENT PARTNERS LIMITED	PATERNOSTER HOUSE, 65 ST PAULS CHURCHYARD, LONDON EC4M 8AB, UNITED KINGDOM

Signature


print name

K. MILLINER

capacity

DIRECTOR

sign here



date

28 / 02 / 17

DIRECTIONS

- (1) If there are a number of substantial holders with similar or related relevant interests (eg. a corporation and its related corporations, or the manager and trustee of an equity trust), the names could be included in an annexure to the form. If the relevant interests of a group of persons are essentially similar, they may be referred to throughout the form as a specifically named group if the membership of each group, with the names and addresses of members is clearly set out in paragraph 4 of the form.
 - (2) See the definition of "relevant interest" in sections 608 and 671B(7) of the Corporations Act 2001.
 - (3) See the definition of "associate" in section 9 of the Corporations Act 2001.
 - (4) Include details of:
 - (a) any relevant agreement or other circumstances because of which the change in relevant interest occurred. If subsection 671B(4) applies, a copy of any document setting out the terms of any relevant agreement, and a statement by the person giving full and accurate details of any contract, scheme or arrangement, must accompany this form, together with a written statement certifying this contract, scheme or arrangement; and
 - (b) any qualification of the power of a person to exercise, control the exercise of, or influence the exercise of, the voting powers or disposal of the securities to which the relevant interest relates (indicating clearly the particular securities to which the qualification applies).

See the definition of "relevant agreement" in section 9 of the Corporations Act 2001.
 - (5) Details of the consideration must include any and all benefits, money and other, that any person from whom a relevant interest was acquired has, or may, become entitled to receive in relation to that acquisition. Details must be included even if the benefit is conditional on the happening or not of a contingency. Details must be included of any benefit paid on behalf of the substantial holder or its associate in relation to the acquisitions, even if they are not paid directly to the person from whom the relevant interest was acquired.
 - (6) The voting shares of a company constitute one class unless divided into separate classes.
 - (7) Give details, if appropriate, of the present association and any change in that association since the last substantial holding notice.
-

ANNEXURE A

This is Annexure A Page 1 of 1 - Cyclopharm Limited (ACN: 116 931 250)

2 Changes in relevant interests

Date of change	Person whose relevant interest changed	Nature of change	Consideration given in relation to change	Class and number of securities affected	Person's votes affected
02.05.13	Lloyds & Casanove Investment Partners Ltd	On Market purchase	\$ 201	1,117	1,117
07.05.13	Lloyds & Casanove Investment Partners Ltd	On Market purchase	\$ 6,342	35,233	35,233
14.05.13	Lloyds & Casanove Investment Partners Ltd	On Market purchase	\$ 2,307	12,746	12,746
22.05.13	Lloyds & Casanove Investment Partners Ltd	On Market purchase	\$ 14,914	82,400	82,400
13.08.13	Lloyds & Casanove Investment Partners Ltd	On Market purchase	\$ 7,079	35,200	35,200
20.08.13	Lloyds & Casanove Investment Partners Ltd	On Market purchase	\$ 2,800	14,000	14,000
21.08.13	Lloyds & Casanove Investment Partners Ltd	On Market purchase	\$ 3,682	18,409	18,409
28.08.13	Lloyds & Casanove Investment Partners Ltd	On Market purchase	\$ 36,679	182,391	182,391
5.12.16	Lloyds & Casanove Investment Partners Ltd	Off Market purchase	\$ 774,291.70	850,870	850,870
30.12.16	Lloyds & Casanove Investment Partners Ltd	Off Market disposal	\$ 9,617,307.70	10,568,470	10,568,470
Total			\$ 10,465,602	11,800,836	11,800,836

Name: K MILLNER

Capacity:

Director

Signed:



Date:

28.02.17